A Synthetic Peptide Homologous to Functional Domain of Human IL-10 Down-Regulates Expression of MHC Class I and Transporter Associated with Antigen Processing 1/2 in Human Melanoma Cells
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Tumor cells treated with IL-10 were shown to have decreased, but peptide-inducible expression of MHC class I, decreased sensitivity to MHC class I-restricted CTL, and increased NK sensitivity. These findings could be explained, at least partially, by a down-regulation of TAP1/TAP2 expression. In this study, IT9302, a nanomeric peptide (AYMTMKIRN), homologous to the C-terminal of the human IL-10 sequence, was demonstrated to mimic these previously described IL-10 effects on MHC class I-related molecules and functions. We observed a dose-dependent down-regulation of MHC class I at the cell surface of melanoma cells after 24-h treatment with IT9302. The IL-10 homologue peptide also caused a dose-dependent inhibition of the IFN-γ-mediated surface induction of MHC class I in a melanoma cell line. We demonstrated, using Western blot and flow cytometry, that IT9302 inhibits the expression of TAP1 and TAP2 proteins, but not MHC class I H chain or low molecular protein molecules. Finally, peptide-treated melanoma cells were shown to be more sensitive to lysis by NK cells in a dose-dependent way. Taken together, these results demonstrate that a small synthetic peptide derived from IL-10 can mimic the Ag presentation-related effects mediated by this cytokine in human melanomas and increase tumor sensitivity to NK cells, which can be relevant in the designing of future strategies for cancer immune therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Waal Malefyt, R., Abrams, J., Bennett, B., Figdor, C. G., & de Vries, J. E. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.5.1209 · Cited by 3,762
IL-10 inhibits cytokine production by activated macrophages
Fiorentino, D. F., Zlotnik, A., Mosmann, T. R., Howard, M., & O’Garra, A. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.11.3815 · Cited by 2,888
Cited by
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
Macrophages in Tumor Microenvironments and the Progression of Tumors
Hao, N.-B., Lü, M.-H., Fan, Y.-H., Cao, Y.-L., Zhang, Z.-R., & Yang, S.-M. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/948098 · Cited by 1,003
Interleukin-10 and the immune response against cancer: a counterpoint
Mocellin, S., Marincola, F. M., & Young, H. A. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0705358 · Cited by 402
Xu, F., Liu, J., Liu, D., Liu, B., Wang, M., Hu, Z., Du, X., Tang, L., & He, F. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2690 · Cited by 373
Inhibitory Effects of B Cells on Antitumor Immunity
Inoue, S., Leitner, W. W., Golding, B., & Scott, D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3766 · Cited by 337
Current status of interleukin-10 and regulatory T-cells in cancer
Dennis, K. L., Blatner, N. R., Gounari, F., & Khazaie, K. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000006 · Cited by 289
“IL-10 could also compromise immune surveillance by changing immunogenicity of the antigen-presenting cell through down-regulation of transporter associated with antigen processing, and therefore antigen presentation by MHC-I and human leukocyte antigen-I [94,95].”
BackgroundInterleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy
Sato, T., Terai, M., Tamura, Y., Alexeev, V., Mastrangelo, M. J., & Selvan, S. R. (2011) · Immunologic Research · doi:10.1007/s12026-011-8262-6 · Cited by 286
Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape
Salazar-Onfray, F., López, M. N., & Mendoza-Naranjo, A. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.01.015 · Cited by 194
Self-citationDual biological effects of the cytokines interleukin-10 and interferon-γ
Wilke, C. M., Wei, S., Wang, L., Kryczek, I., Kao, J., & Zou, W. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1104-5 · Cited by 138
Metadata
- Authors
- Kurte, M., López, M., Aguirre, A., Escobar, A., Aguillón, J. C., Charo, J., Larsen, C. G., Kiessling, R., & Salazar-Onfray, F.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-08-01
- Volume
- 173
- Issue
- 3
- Pages
- 1731-1737
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1496671606
- Cited by
- 86
- References
- 2
- FWCI
- 1.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.